Sponsor Overview
Explore verified public information about UroGen Pharma Ltd.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“UroGen® has engaged Tanner Pharma Group to administer a Named Patient Program for Jelmyto® (mitomycin) for pyelocalyceal solution in select countries where Jelmyto is currently not available or approved for use by the local regulatory authority. This program provides controlled, pre-approval access to Jelmyto in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where Jelmyto has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 1 supporting sources.
Conditions: Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Carcinoma, Urothelial Carcinoma Recurrent
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.